Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Trump Buys SpaceX Shares After Record IPO 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Tesla Raises Cybertruck Prices by $5,000 in US 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
 & Lead Plaintiff Deadline: June 4, 2018 - EconoTimes)
Add as a preferred source on Google
NEW YORK, April 20, 2018 -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (NASDAQ:CGIX) and certain of its officers, on behalf of shareholders who purchased Cancer Genetics securities between March 23, 2017 and April 2, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/cgix.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Cancer Genetics had ineffective disclosure controls and internal controls over financial reporting; and (2) consequently, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/cgix or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Cancer Genetics you have until June 4, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
